Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting anti-tumor immunity.

ABSTRACT: Immune checkpoint inhibition (ICI) has improved clinical outcomes for certain patients with cancer. However, only a minority of patients have durable responses with underlying causes of differential immune responses across individuals often being unknown. Lifestyle exposures impact immune function and may subsequently alter the response to ICI. Alcohol use is common among cancer patients with known detrimental effects on adaptive immune function. However, its impact on ICI efficacy remains unknown. To determine if alcohol impacts ICI therapies, we performed a retrospective assessment of outcomes for patients receiving anti-PD1 ICI across tumor types and employed preclinical mouse models of ICI for lung and bladder cancer. Alcohol use reduced ICI efficacy in human patients treated with anti

SUBMITTER: Gilley KN 

PROVIDER: S-EPMC12306839 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature